$HURA

2022 Q4 Form 10-Q Financial Statement

#000095017022023988 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.440M $1.475M
YoY Change -27.75% -32.28%
% of Gross Profit
Research & Development $2.059M $3.171M
YoY Change -47.23% -16.4%
% of Gross Profit
Depreciation & Amortization $15.00K $15.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $3.499M $4.646M
YoY Change -40.64% -22.19%
Operating Profit
YoY Change
Interest Expense $45.00K $50.00K
YoY Change 2150.0% 900.0%
% of Operating Profit
Other Income/Expense, Net $45.00K $50.00K
YoY Change 2150.0% 900.0%
Pretax Income -$3.454M -$4.596M
YoY Change -41.39% -22.96%
Income Tax
% Of Pretax Income
Net Earnings -$3.454M -$4.596M
YoY Change -41.39% -22.96%
Net Earnings / Revenue
Basic Earnings Per Share -$2.10 -$0.07
Diluted Earnings Per Share -$2.10 -$3.139M
COMMON SHARES
Basic Shares Outstanding 80.81M 80.81M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.874M $7.085M
YoY Change -65.34% -63.36%
Cash & Equivalents $4.874M $7.085M
Short-Term Investments
Other Short-Term Assets $4.304M $1.071M
YoY Change 360.81% 39.27%
Inventory
Prepaid Expenses $1.079M $1.071M
Receivables
Other Receivables
Total Short-Term Assets $9.178M $8.156M
YoY Change -38.81% -59.44%
LONG-TERM ASSETS
Property, Plant & Equipment $739.0K $754.0K
YoY Change 515.83% 458.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $4.300M
YoY Change -100.0% 104.76%
Total Long-Term Assets $739.0K $5.054M
YoY Change -72.83% 126.13%
TOTAL ASSETS
Total Short-Term Assets $9.178M $8.156M
Total Long-Term Assets $739.0K $5.054M
Total Assets $9.917M $13.21M
YoY Change -44.03% -40.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.691M $2.943M
YoY Change -7.05% 17.25%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.239M $3.516M
YoY Change -5.79% 17.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.00K $76.00K
YoY Change -55.06% -57.54%
Total Long-Term Liabilities $80.00K $76.00K
YoY Change -55.06% -57.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.239M $3.516M
Total Long-Term Liabilities $80.00K $76.00K
Total Liabilities $3.319M $3.592M
YoY Change -8.21% 12.96%
SHAREHOLDERS EQUITY
Retained Earnings -$144.8M -$141.3M
YoY Change 15.31% 18.1%
Common Stock $140.6M $138.4M
YoY Change 10.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.598M $9.618M
YoY Change
Total Liabilities & Shareholders Equity $9.917M $13.21M
YoY Change -44.03% -40.88%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.454M -$4.596M
YoY Change -41.39% -22.96%
Depreciation, Depletion And Amortization $15.00K $15.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$2.161M -$6.369M
YoY Change -57.66% 25.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $859.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$232.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.00K 1.906M
YoY Change -70.76% -86.26%
NET CHANGE
Cash From Operating Activities -2.161M -6.369M
Cash From Investing Activities 0.000 -232.0K
Cash From Financing Activities -50.00K 1.906M
Net Change In Cash -2.211M -4.695M
YoY Change -58.09% -153.34%
FREE CASH FLOW
Cash From Operating Activities -$2.161M -$6.369M
Capital Expenditures $0.00 $859.0K
Free Cash Flow -$2.161M -$7.228M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001498382
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-37823
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
Kintara Therapeutics, Inc.
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0360497
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
9920 Pacific Heights Blvd
CY2022Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022Q3 dei City Area Code
CityAreaCode
858
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
350-4364
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q3 dei Trading Symbol
TradingSymbol
KTRA
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
80807316
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7085000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11780000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1071000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1478000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
8156000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
13258000
CY2022Q3 ktra Clinical Trial Deposit Non Current
ClinicalTrialDepositNonCurrent
4300000
CY2022Q2 ktra Clinical Trial Deposit Non Current
ClinicalTrialDepositNonCurrent
2600000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
754000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
721000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3516000
CY2022Q3 us-gaap Assets
Assets
13210000
CY2022Q2 us-gaap Assets
Assets
15948000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2943000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3269000
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
573000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3990000
CY2022Q3 ktra Milestone Payment Liability
MilestonePaymentLiability
76000
CY2022Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
163000
CY2022Q3 us-gaap Liabilities
Liabilities
3592000
CY2022Q2 us-gaap Liabilities
Liabilities
4153000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80807000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65533000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
81000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
66000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
138278000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
135510000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141316000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136356000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9618000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11795000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13210000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15948000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3171000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3793000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1475000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2178000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4646000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5971000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
39000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4596000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5966000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4596000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5966000
CY2022Q3 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
2000
CY2021Q3 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
2000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4960000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8430000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73205000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34281000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11795000
CY2022Q3 ktra Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
1903000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
518000
CY2022Q3 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4596000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9618000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
10581000
CY2021Q3 ktra Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
13634000
CY2021Q3 ktra Exercise Of2020 Investor Warrants For Cash
ExerciseOf2020InvestorWarrantsForCash
69000
CY2021Q3 ktra Exercise Of Pre Funded Warrants For Cash
ExerciseOfPreFundedWarrantsForCash
5000
CY2021Q3 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
31000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
811000
CY2021Q3 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5966000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
19163000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4596000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5966000
CY2022Q3 us-gaap Depreciation
Depreciation
15000
CY2021Q3 us-gaap Depreciation
Depreciation
15000
CY2022Q3 ktra Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
87000
CY2021Q3 ktra Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
3000
CY2021Q3 ktra Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
31000
CY2022Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
518000
CY2021Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
811000
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13000
CY2022Q3 ktra Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
-1700000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-331000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
122000
CY2022Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-148000
CY2021Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-70000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6369000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5073000
CY2022Q3 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
232000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232000
CY2022Q3 ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
1908000
CY2021Q3 ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
13803000
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
74000
CY2022Q3 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
2000
CY2021Q3 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
2000
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1906000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13875000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4695000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8802000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11780000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10537000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7085000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19339000
CY2022Q3 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 Nature of operations, corporate history, and going concern and management plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of operations</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate history</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero") in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC ("Nasdaq") under the symbol “KTRA”.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Going concern and management plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended September 30, 2022, the Company reported a loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,596</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and a negative cash flow from operations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,369</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,316</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,085</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of September 30, 2022. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On August 2, 2022, the Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entered into a stock purchase agreement under which the Company ultimately received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,908</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in net proceeds as of September 30, 2022 which is the current maximum available under the stock purchase agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even with the proceeds from this financing, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of filing of these condensed consolidated interim financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or the entering into of strategic partnership arrangements but the ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These condensed consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</span></p>
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4596000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6369000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141316000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7085000
CY2022Q3 ktra Substantial Doubt About Companys Ability To Continues Going Concern Period
SubstantialDoubtAboutCompanysAbilityToContinuesGoingConcernPeriod
P1Y
CY2022Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</span></p>
CY2022Q3 ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
1840000
CY2021Q3 ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
1952000
CY2022Q3 ktra Clinical Trial Deposit Payments
ClinicalTrialDepositPayments
1700000
CY2022Q3 ktra Deposits Payments
DepositsPayments
4300000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90000
CY2022Q3 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
679000
CY2022Q3 us-gaap Depreciation
Depreciation
15000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
754000
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
859000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
180000
CY2022Q3 ktra Capitalized Cost Of Property And Equipment Not In Use
CapitalizedCostOfPropertyAndEquipmentNotInUse
679000
CY2021Q3 us-gaap Depreciation
Depreciation
15000
CY2022Q3 us-gaap Depreciation
Depreciation
15000
CY2022Q3 ktra Capitalized Cost Of Property And Equipment In Use
CapitalizedCostOfPropertyAndEquipmentInUse
180000
CY2021Q3 ktra Capitalized Cost Of Property And Equipment In Use
CapitalizedCostOfPropertyAndEquipmentInUse
180000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
7444000
CY2022Q3 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
0.63
CY2022Q3 ktra Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y4M13D
CY2021Q3 ktra Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y10D
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
573000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
721000
CY2022Q3 ktra Underwritten Public Offerings Description
UnderwrittenPublicOfferingsDescription
the Company closed on the sale of (i) 7,200 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12291000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4847000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
518000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
811000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4199000
CY2022Q2 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
1.02
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3481000
CY2022Q3 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
0.18
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
236000
CY2022Q3 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
1.05
CY2022Q3 ktra Non Cash Issue Costs
NonCashIssueCosts
289000
CY2021Q3 ktra Non Cash Issue Costs
NonCashIssueCosts
333000
CY2022Q3 ktra Issue Costs In Accounts Payable And Accrued Liabilities
IssueCostsInAccountsPayableAndAccruedLiabilities
48000
CY2021Q3 ktra Issue Costs In Accounts Payable And Accrued Liabilities
IssueCostsInAccountsPayableAndAccruedLiabilities
169000
CY2022Q3 ktra Equipment Additions Reclassified From Prepaid Expenses
EquipmentAdditionsReclassifiedFromPrepaidExpenses
447000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-023988-index-headers.html Edgar Link pending
0000950170-22-023988-index.html Edgar Link pending
0000950170-22-023988.txt Edgar Link pending
0000950170-22-023988-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img138745081_0.jpg Edgar Link pending
img138745081_1.jpg Edgar Link pending
ktra-20220930.htm Edgar Link pending
ktra-20220930.xsd Edgar Link pending
ktra-ex31_1.htm Edgar Link pending
ktra-ex31_2.htm Edgar Link pending
ktra-ex32_1.htm Edgar Link pending
ktra-ex32_2.htm Edgar Link pending
ktra-ex3_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
ktra-20220930_cal.xml Edgar Link unprocessable
ktra-20220930_pre.xml Edgar Link unprocessable
ktra-20220930_lab.xml Edgar Link unprocessable
ktra-20220930_def.xml Edgar Link unprocessable
ktra-20220930_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending